Get the Stockscreener App
54.50
1.77%
0.95
Royalty Pharma Plc stock is traded at $54.50, with a volume of 3.05M.
It is up +1.77% in the last 24 hours and up +9.61% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$53.55
Open:
$53.81
24h Volume:
3.05M
Relative Volume:
0.95
Market Cap:
$24.16B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
28.54
EPS:
1.9093
Net Cash Flow:
$574.14M
1W Performance:
+3.12%
1M Performance:
+9.61%
6M Performance:
+40.03%
1Y Performance:
+68.68%
1-Day Range:
$53.69
$54.63
1-Week Range:
$51.81
$54.63
52-Week Range:
$32.15
$54.63
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
54.50 | 23.74B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma stock hits 52-week high at 53.48 USD By Investing.com - Investing.com Australia
Royalty Pharma PLC $RPRX Shares Bought by Handelsbanken Fonder AB - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 13,684 Shares of Stock - MarketBeat
Royalty Pharma EVP Marshall Urist sells $721,837 in shares - Investing.com
Royalty Pharma EVP Marshall Urist sells $721,837 in shares By Investing.com - Investing.com Canada
Royalty Pharma (RPRX) EVP Urist sells 13,684 shares in 10b5-1 planned trade - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month HighWhat's Next? - MarketBeat
Royalty Pharma stock hits 52-week high at 53.48 USD - Investing.com
Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $4.92 Million in Royalty Pharma PLC $RPRX - MarketBeat
Thrivent Financial for Lutherans Acquires 22,015 Shares of Royalty Pharma PLC $RPRX - MarketBeat
49,855 Shares in Royalty Pharma PLC $RPRX Acquired by Partners Group Holding AG - MarketBeat
Marathon Asset Management Ltd Has $15 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Acquired by Cullen Frost Bankers Inc. - MarketBeat
RPRX: Royalty financing is rapidly growing, with flexible deals and global expansion fueling future growth - TradingView
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance - Insider Monkey
Royalty Pharma plc (RPRX) Investor Outlook: Strong Buy Ratings and Solid Growth Prospects - DirectorsTalk Interviews
Qsemble Capital Management LP Invests $2.88 Million in Royalty Pharma PLC $RPRX - MarketBeat
Commerzbank Aktiengesellschaft FI Invests $982,000 in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead - Seeking Alpha
Royalty Pharma EVP Urist sells $726,137 in shares - Investing.com UK
Royalty Pharma EVP Urist sells $726,137 in shares By Investing.com - Investing.com Nigeria
Royalty Pharma (RPRX) EVP sells 13,684 shares under 10b5-1 plan - Stock Titan
Rule 10b5-1 sale by Royalty Pharma (RPRX) director Gregory Norden - Stock Titan
Understanding the Setup: (RPRX) and Scalable Risk - Stock Traders Daily
Press Release: Royalty Pharma Declares Second Quarter 2026 Dividend - Moomoo
Royalty Pharma (NASDAQ: RPRX) insider sale notice — 3,045 shares - Stock Titan
[144] Royalty Pharma plc SEC Filing - Stock Titan
Capital International (RPRX) amendment shows 8.8% stake in Royalty Pharma - Stock Titan
Royalty Pharma (RPRX) Valuation Check After Strong Q1 Earnings And Rising Investor Interest - Sahm
Royalty Pharma stock hits 52-week high at 52.16 USD By Investing.com - Investing.com Nigeria
RPRX: Expanding royalty financing, robust pipeline, and strong capital position drive future growth - TradingView
Royalty Pharma stock hits 52-week high at 52.16 USD - Investing.com India
Royalty pharma – funding the next generation of medicines - Livewire Markets
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend Soon - Yahoo Finance
Hosking Partners LLP Purchases 155,450 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Healthcare Giant with a Promising 16.66% Potential Upside - DirectorsTalk Interviews
C WorldWide Group Holding A S Has $27.07 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Accelerated Royalty Deals and Dividend Hike Could Be A Game Changer For Royalty Pharma (RPRX) - simplywall.st
MSN Money - MSN
Royalty Pharma (NASDAQ:RPRX) Upgraded at Wall Street Zen - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
Christopher Hite gains 24,263 Royalty Pharma (RPRX) shares via equity award - Stock Titan
Royalty Pharma (RPRX) EVP gets 18,197-share equity award - Stock Titan
10% Of This Royalty Pharma Insider's Holdings Were Sold - Yahoo Finance
Royalty Pharma raises 2026 portfolio receipts guidance to $3.325B-$3.45B as it scales R&D co-funding - MSN
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.33%
3.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):